{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:29:16Z","timestamp":1768901356274,"version":"3.49.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,1,3]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We examined patient-reported outcomes (PROs) in The Study of Etanercept And Methotrexate in Patients with Psoriatic Arthritis (PsA); a 48-week, phase 3, randomised controlled trial that compared outcomes with methotrexate (MTX) monotherapy, etanercept monotherapy, and MTX+ etanercept in patients with PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Efficacy endpoints included: mean changes from baseline and proportion of patients who reported improvements\u2265minimal clinically important difference (MCID) at week 24 in treatment groups for Health Assessment Questionnaire-Disability Index, Patient Global Assessment (PtGA), Patient Global Assessment of Joint Pain (PtGAJP) and Medical Outcomes Study Short Form-36 Questionnaire (SF-36) Physical Component Summary (PCS), and Mental Component Summary, and eight domain scores. PROs were analysed as reported (observed), without multiplicity adjustment; therefore, p values are descriptive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 24, patients receiving etanercept monotherapy or MTX+ etanercept combination reported greater improvements (p\u22640.05) in PtGA, PtGAJP and SF-36 PCS scores compared with those receiving MTX monotherapy. Compared with MTX monotherapy, higher proportions of patients receiving etanercept monotherapy and combination therapy reported improvements\u2265MCID in PtGA (etanercept vs MTX, p=0.005) and PtGAJP (MTX +etanercept vs MTX, p=0.038). Across PROs, proportions of patients reporting scores\u2265age\u2009and gender-matched normative values at week 24 ranged from 20.8% to 51.0% with MTX monotherapy, 30.9% to 48.8% with etanercept monotherapy, and 30.6% to 52.3% with MTX+ etanercept combination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients receiving etanercept monotherapy or MTX+ etanercept reported greater improvements from baseline in several PROs compared with those receiving MTX monotherapy. PROs should be incorporated in discussions between patients and clinicians regarding their treatment choices as they can help determine which treatments are more beneficial in patients with PsA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001484","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T11:40:28Z","timestamp":1610710828000},"page":"e001484","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02376790","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"first","affiliation":[{"name":"Immunology\/Rheumatology, Stanford University, Stanford, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"School of Medicine, Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-3061","authenticated-orcid":false,"given":"Ervant J","family":"Maksabedian Hernandez","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley S","family":"Stolshek","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyrica X H","family":"Liu","sequence":"additional","affiliation":[{"name":"Global Biostatistical Science, Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H","family":"Collier","sequence":"additional","affiliation":[{"name":"US Medical Organization, Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Kricorian","sequence":"additional","affiliation":[{"name":"US Medical Organization, Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"2025090313335116000_7.1.e001484.1","first-page":"s216","article-title":"Psoriasis and psoriatic arthritis overview","volume":"22","author":"Menter","year":"2016","journal-title":"Am J Manag Care"},{"key":"2025090313335116000_7.1.e001484.2","first-page":"69","article-title":"Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report","volume":"146","author":"Biondi Oriente","year":"1989","journal-title":"Acta Derm Venereol Suppl"},{"key":"2025090313335116000_7.1.e001484.3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313335116000_7.1.e001484.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(05)70376-4"},{"key":"2025090313335116000_7.1.e001484.5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090313335116000_7.1.e001484.6","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"key":"2025090313335116000_7.1.e001484.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker365"},{"key":"2025090313335116000_7.1.e001484.8","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948130"},{"key":"2025090313335116000_7.1.e001484.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200387"},{"key":"2025090313335116000_7.1.e001484.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081015"},{"key":"2025090313335116000_7.1.e001484.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090313335116000_7.1.e001484.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu264"},{"key":"2025090313335116000_7.1.e001484.13","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0032-x"},{"key":"2025090313335116000_7.1.e001484.14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2025090313335116000_7.1.e001484.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064808"},{"key":"2025090313335116000_7.1.e001484.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes001"},{"key":"2025090313335116000_7.1.e001484.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214746"},{"key":"2025090313335116000_7.1.e001484.18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313335116000_7.1.e001484.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090313335116000_7.1.e001484.20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000606"},{"key":"2025090313335116000_7.1.e001484.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110392"},{"key":"2025090313335116000_7.1.e001484.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090832"},{"key":"2025090313335116000_7.1.e001484.23","doi-asserted-by":"crossref","first-page":"2077.2","DOI":"10.3899\/jrheum.101256","article-title":"Minimal important difference and responsiveness to change of the SF-36 in patients with psoriatic arthritis receiving tumor necrosis factor-\u03b1 blockers","volume":"38","author":"Leung","year":"2011","journal-title":"J Rheumatol"},{"key":"2025090313335116000_7.1.e001484.24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","article-title":"Patient-reported outcomes in psoriatic arthritis","volume":"42","author":"Orbai","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090313335116000_7.1.e001484.25","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-20"},{"key":"2025090313335116000_7.1.e001484.26","unstructured":"Ware JE , Kosinski M , Bjorner JB . Trust MO , ed. User\u2019s manual for the SF-36v2 Health Survey. Lincoln, RI: QualityMetric Incorporated, 2007."},{"key":"2025090313335116000_7.1.e001484.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.115550"},{"key":"2025090313335116000_7.1.e001484.28","doi-asserted-by":"publisher","DOI":"10.1177\/2040622312459673"},{"key":"2025090313335116000_7.1.e001484.29","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2010.0384"},{"key":"2025090313335116000_7.1.e001484.30","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/art.40872","article-title":"SEAM-PsA: seems like methotrexate works in psoriatic arthritis?","volume":"71","author":"Merola","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:34:00Z","timestamp":1756931640000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,15]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/rmdopen-2020-001484"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001484","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}